Toyoda Gosei Invests in Craif, Inc., a Startup Developing Urine Test Kits for Higher Possibility of the Early Detection of Cancer
KIYOSU,
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240304365301/en/
miSignal cancer risk test kit (Photo: Business Wire)
With its expertise in nanometer level processing technology in the bioscience field, Craif develops and sells test kits that can easily and highly sensitively detect the risks of seven types of cancer, including pancreatic and lung cancer, as early as cancer stage 1. These kits comprehensively and efficiently capture and measure small microRNA molecules called miRNA2 in urine, which are generally difficult to detect. Higher accuracy is achieved in combination with the tests using AI analysis.
1 Investment made in
2 The amount and type of miRNA contained in urine differs depending on the type of cancer and its progression. This makes miRNA contribute to the detection of the cancer risk.
Outline of
|
|
Location |
5F Hongo ITP Office, 2-25-7 Yushima, Bunkyo-ku, |
CEO |
|
Established |
|
Capital |
|
View source version on businesswire.com: https://www.businesswire.com/news/home/20240304365301/en/
Contact: Public Relations
inquiry@mlist.toyoda-gosei.co.jp
Source: